Antecedents of Gastronomy Destination Brand Equity: An Examination of Gastronomy Experience, Motivation, and Destination Satisfaction
Advances in Hospitality and Tourism Research (AHTR) · 2023
DOI: 10.30519/ahtr.1009968 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Hospitality and Tourism Research (AHTR), 2023. Verfasst von Davut KODAŞ und 1 weiteren Autor:innen. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 111 Literaturangaben.
Abstract (Originalsprache)
This paper aims to test the relationships among gastronomic experience, motivation, destination satisfaction, and gastronomy destination brand equity. Data (n:600) was gathered from domestic visitors visiting Gaziantep in March, April to May 2018. Scale development to measure gastronomy experiences and scale adaptation process of destination brand equity were carried out. The relationships among the variables were examined with structural equation modeling. According to the findings, except H5 and H8, all hypotheses are significant in the research model. At the end of the study, significant theoretical and managerial implications were provided for the tourism providers and destination marketers, and managers.
Zitieren
APA
KODAŞ, D., & ÖZEL, Ç. H. (2023). Antecedents of Gastronomy Destination Brand Equity: An Examination of Gastronomy Experience, Motivation, and Destination Satisfaction. Advances in Hospitality and Tourism Research (AHTR). https://doi.org/10.30519/ahtr.1009968
Vancouver
KODAŞ D, ÖZEL ÇH. Antecedents of Gastronomy Destination Brand Equity: An Examination of Gastronomy Experience, Motivation, and Destination Satisfaction. Advances in Hospitality and Tourism Research (AHTR). 2023. doi:10.30519/ahtr.1009968
BibTeX
@article{KODA2023,
author = {KODAŞ, Davut and ÖZEL, Çağıl Hale},
title = {Antecedents of Gastronomy Destination Brand Equity: An Examination of Gastronomy Experience, Motivation, and Destination Satisfaction},
journal = {Advances in Hospitality and Tourism Research (AHTR)},
year = {2023},
doi = {10.30519/ahtr.1009968}
}
EUVIMED